Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 22, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Repurchased: 2,500,000 ordinary shares.
- Price per Share: 1,348.26 pence.
- Treasury Shares Held: 297,697,678 shares (representing 4.94% of total voting rights).
- Shares in Issue: 5,722,481,706 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 2,500,000 shares on May 22, 2007. Consequently, the total number of shares held in Treasury increased to 297,697,678. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (2,500,000 shares at 1,348.26 pence each).
- Confirm the updated percentage of Treasury shares relative to total voting rights (4.94%).
- Check the current number of shares in issue (5,722,481,706) for accurate calculation of ownership thresholds under Disclosure and Transparency Rules.
- Note that this filing does not contain financial results; investors should refer to Form 20-F or quarterly reports for revenue and earnings data.